Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumour activity of novel quinazolines

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 21, 1997, Pages 2723-2728

  Gibson, K H ^a   Grundy, W ^a   Godfrey, A A ^a   Woodburn, J R ^a   Ashton, S E ^a   Curry, B J ^a   Scarlett, L ^a   Barker, A J ^a   Brown, D S ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CELL STRAIN KB; CHEMICAL MODIFICATION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN CELL; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; STRUCTURE ACTIVITY RELATION; TUMOR;

EID: 0030779452     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)10059-2     Document Type: Article

References (15)

1. Barker, A. J.; Davies, D. H., Eur. Pat. Appl. EP 520722, 1992. Barker, A. J., Eur. Pat. Appl. EP 566226, 1993. Barker, A. J.; Brown, D. S., Eur. Pat. Appl. EP 602851, 1994. Barker, A. J., Eur. Pat. Appl. EP 635498, 1995.
2. Barker, A. J.; Davies, D. H., Eur. Pat. Appl. EP 520722, 1992. Barker, A. J., Eur. Pat. Appl. EP 566226, 1993. Barker, A. J.; Brown, D. S., Eur. Pat. Appl. EP 602851, 1994. Barker, A. J., Eur. Pat. Appl. EP 635498, 1995.
3. Barker, A. J.; Davies, D. H., Eur. Pat. Appl. EP 520722, 1992. Barker, A. J., Eur. Pat. Appl. EP 566226, 1993. Barker, A. J.; Brown, D. S., Eur. Pat. Appl. EP 602851, 1994. Barker, A. J., Eur. Pat. Appl. EP 635498, 1995.
4. Barker, A. J.; Davies, D. H., Eur. Pat. Appl. EP 520722, 1992. Barker, A. J., Eur. Pat. Appl. EP 566226, 1993. Barker, A. J.; Brown, D. S., Eur. Pat. Appl. EP 602851, 1994. Barker, A. J., Eur. Pat. Appl. EP 635498, 1995.
5. Ward, W. H. J.; Cook, P.N.; Slater, A.M.; Davies, D. H.; Holdgate, G. A.; Green, L. R. Biochem. Pharmacol. 1994, 48, 659.
6. Wakeling, A. E.; Barker, A. J.; Davies, D. H.; Brown, D. S.; Green, L. R.; Cartlidge S. A.; Woodburn, J. R. Breast Cancer Research and Treatment 1996, 38, 67.
7. For a recent review and additional references see: Fry, D. W. In Annual Reports in Medicinal Chemistry, Academic, 1996; Vol. 31, Chap. 16, pp 151-160.
8. Barker, A. J., Eur. Pat. Appl. EP 566226, 1993. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W.; J. Med. Chem. 1995, 38, 3482.
9. Barker, A. J., Eur. Pat. Appl. EP 566226, 1993. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W.; J. Med. Chem. 1995, 38, 3482.
10. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D. H.; Fry, D. W.; Kraker, A. J.; Denny, W. A. J. Med. Chem. 1996, 39, 267.
11. Myers, M. R.; Setzer, N. N.; Spada, A. P.; Zulli, A. L.; Hsu, C-Y. J.; Zilberstein, A.; Johnson, S. E.; Hook, L. E.; Jacoski, M. V. Bioorg. Med. Chem. Lett. 1997, 417.
12. The inhibition of EGF-RTK activity by compound 3 has been reported previously in Ref. 9.
13. Myers, M. R.; Setzer, N. N.; Spada, A. P.; Persons, P. E.; Ly, C. Q.; Maguire, M. P.; Zulli, A. L.; Cheney, D. L.; Zilberstein, A.; Johnson, S. E.; Franks, C. F.; Mitchell, K. J. Bioorg. Med. Chem. Lett. 1997, 421.
14. Bridges, A. J.; Cody, D. R.; Zhou, H.; McMichael, A.; Fry, D. W. Bioorg. Med. Chem. 1995, 3, 1651.
15. Gibson, K. H., PCT Int. Appl. WO 96 33980, 1996.